Top

Published in:

01-06-2015 | Research Paper

Loss of PCDH9 is associated with the differentiation of tumor cells and metastasis and predicts poor survival in gastric cancer

Authors: Ying Chen, Honggang Xiang, Yingfan Zhang, Jiejun Wang, Guanzhen Yu

Published in: Clinical & Experimental Metastasis | Issue 5/2015

Abstract

Microarray studies revealed down-regulation of PCDH9 mRNA level in lymph node metastasis of gastric cancer compared with the primary tumors. The expression of PCDH9 protein and its clinicopathological relevance were assessed on tissue microarrays of 1072 cases of gastric cancer. Its prognostic value was further evaluated on a small cohort of 175 gastric cancers. PCDH9 was down-regulated during the development and progression of gastric cancer. The overall rates of PCDH9 expression in normal, primary tumor, nodal and hepatic metastatic tissues were 100 % (1072/1072), 48.0 % (515/1072), 20.1 % (34/169), and 5.6 % (1/18), respectively. Positive staining of PCDH9 protein was significantly reversely correlated with tumor size, tumor differentiation, tumor invasion, lymph node metastasis, and disease progression. The Cox proportional hazards model revealed that the PCDH9 was an independent prognostic factor for gastric cancer. Therefore, decreased expression of PCDH9 is frequent in human gastric cancer metastasis and PCDH9 expression is an independent prognostic factor, suggesting that PCDH9 could be a promising biomarker of this malignancy.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef

Akagi T, Shiraishi N, Kitano S (2011) Lymph node metastasis of gastric cancer. Cancers 3(2):2141–2159PubMedCentralPubMedCrossRef

Hunter KW, Crawford NP, Alsarraj J (2008) Mechanisms of metastasis. Breast Cancer Res 10(Suppl 1):S2PubMedCentralPubMedCrossRef

Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K (2009) Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 15(5):1821–1829PubMedCrossRef

Fokas E, Engenhart-Cabillic R, Daniilidis K, Rose F, An HX (2007) Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev 26(3–4):705–715PubMedCrossRef

Yu G, Wang J, Chen Y, Wang X, Pan J, Li Q, Xie K (2008) Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis 25(7):695–702PubMedCrossRef

Deng JY, Liang H (2014) Clinical significance of lymph node metastasis in gastric cancer. World J Gastroenterol 20(14):3967–3975PubMedCentralPubMedCrossRef

Li W, Ye F, Wang D, Sun X, Tong W, Lian G, Jiang J, Suo J, Zhang DY (2013) Protein predictive signatures for lymph node metastasis of gastric cancer. Int J Cancer 132(8):1851–1859PubMedCrossRef

Huynh KT, Hoon DS (2012) Epigenetics of regional lymph node metastasis in solid tumors. Clin Exp Metastasis 29(7):747–756PubMedCrossRef

10.

Leong SP, Witte M (2012) Biomarkers of cancer metastasis through the lymphovascular system: future perspectives. Clin Exp Metastasis 29(7):861–864PubMedCrossRef

11.

Ojetti V, Persiani R, Cananzi FC, Sensi C, Piscaglia AC, Saulnier N, Biondi A, Gasbarrini A, D’Ugo D (2014) cDNA-microarray analysis as a new tool to predict lymph node metastasis in gastric cancer. World J Surg 38(8):2058–2064PubMedCrossRef

12.

Xu Y, Liu Z, Guo K (2012) Expression of FHL1 in gastric cancer tissue and its correlation with the invasion and metastasis of gastric cancer. Mol Cell Biochem 363(1–2):93–99PubMedCrossRef

13.

Li P, Qian J, Yu G, Chen Y, Liu K, Li J, Wang J (2012) Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer. J Surg Oncol 105(1):31–37PubMedCrossRef

14.

Redies C, Vanhalst K, Roy F (2005) delta-Protocadherins: unique structures and functions. Cell Mol Life Sci 62(23):2840–2852PubMedCrossRef

15.

Yu B, Yang H, Zhang C, Wu Q, Shao Y, Zhang J, Guan M, Wan J, Zhang W (2010) High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers. Neoplasma 57(3):247–252PubMedCrossRef

16.

Okazaki N, Takahashi N, Kojima S, Masuho Y, Koga H (2002) Protocadherin LKC, a new candidate for a tumor suppressor of colon and liver cancers, its association with contact inhibition of cell proliferation. Carcinogenesis 23(7):1139–1148PubMedCrossRef

17.

Jung SP, Kim S, Nam SJ, Kim I, Bae JW (2013) The role of the CDH1 promoter hypermethylation in the axillary lymph node metastasis and prognosis. J Breast Cancer 16(1):16–22PubMedCentralPubMedCrossRef

18.

Yuecheng Y, Hongmei L, Xiaoyan X (2006) Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis 23(1):65–74PubMedCrossRef

19.

Yu GZ, Chen Y, Long YQ, Dong D, Mu XL, Wang JJ (2008) New insight into the key proteins and pathways involved in the metastasis of colorectal carcinoma. Oncol Rep 19(5):1191–1204PubMed

20.

Gao Y, Chen Y, Xu D, Wang J, Yu G (2014) Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers. BMC Cancer 14:520PubMedCentralPubMedCrossRef

21.

Pang JZ, Qin LX, Ren N, Hei ZY, Ye QH, Jia WD, Sun BS, Lin GL, Liu DY, Liu YK et al (2007) Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma. Clin Cancer Res 13(24):7363–7369PubMedCrossRef

22.

Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M et al (2008) PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 27(34):4657–4665PubMedCentralPubMedCrossRef

23.

Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F, Ohki M, Hirohashi S, Inazawa J (2006) Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 66(9):4617–4626PubMedCrossRef

24.

Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM et al (2009) Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136(2):640–651PubMedCrossRef

25.

Kim SY, Chung HS, Sun W, Kim H (2007) Spatiotemporal expression pattern of non-clustered protocadherin family members in the developing rat brain. Neuroscience 147(4):996–1021PubMedCrossRef

26.

Strehl S, Glatt K, Liu QM, Glatt H, Lalande M (1998) Characterization of two novel protocadherins (PCDH8 and PCDH9) localized on human chromosome 13 and mouse chromosome 14. Genomics 53(1):81–89PubMedCrossRef

27.

Wang C, Yu G, Liu J, Wang J, Zhang Y, Zhang X, Zhou Z, Huang Z (2012) Downregulation of PCDH9 predicts prognosis for patients with glioma. J Clin Neurosci 19(4):541–545PubMedCrossRef

28.

Yu G, Gao Y, Ni C, Chen Y, Pan J, Wang X, Ding Z, Wang J (2011) Reduced expression of EphB2 is significantly associated with nodal metastasis in Chinese patients with gastric cancer. J Cancer Res Clin Oncol 137(1):73–80PubMedCrossRef

29.

Jao TM, Tsai MH, Lio HY, Weng WT, Chen CC, Tzeng ST, Chang CY, Lai YC, Yen SJ, Yu SL et al (2014) Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis. Int J Cancer 135(11):2593–2603PubMedCrossRef

30.

Hu X (2014) Risk factors and prognosis of liver metastasis from gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 17(2):108–111PubMed

31.

Wang Y, Liu YF, Cheng Y, Yi DH, Li P, Song WQ, Fu DZ, Wang X (2010) Prognosis of colorectal cancer with liver metastasis: value of a prognostic index. Braz J Med Biol Res 43(11):1116–1122PubMedCrossRef

32.

Ozturk E, Kilicturgay S, Yilmazlar T, Zorluoglu A, Ozen Y (2010) Factors affecting the prognosis of patients with colorectal liver metastasis. Acta Chir Belg 110(2):189–194PubMed

33.

Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W, Bigner D, Yan H, Waldman T (2009) Sample type bias in the analysis of cancer genomes. Cancer Res 69(14):5630–5633PubMedCentralPubMedCrossRef

34.

Kim SY, Yasuda S, Tanaka H, Yamagata K, Kim H (2011) Non-clustered protocadherin. Cell Adh Migr 5(2):97–105PubMedCentralPubMedCrossRef

35.

Bouillot S, Tillet E, Carmona G, Prandini MH, Gauchez AS, Hoffmann P, Alfaidy N, Cand F, Huber P (2011) Protocadherin-12 cleavage is a regulated process mediated by ADAM10 protein: evidence of shedding up-regulation in pre-eclampsia. J Biol Chem 286(17):15195–15204PubMedCentralPubMedCrossRef

Title: Loss of PCDH9 is associated with the differentiation of tumor cells and metastasis and predicts poor survival in gastric cancer
Authors: Ying Chen
Honggang Xiang
Yingfan Zhang
Jiejun Wang
Guanzhen Yu
Publication date: 01-06-2015
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5/2015
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-015-9712-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

NANOG signaling promotes metastatic capability of immunoedited tumor cells

Amino-terminal fragments of laminin γ2 chain stimulate migration of metastatic breast cancer cells by interacting with CD44

Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases

Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion

Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers

Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer